Higher Renal Replacement Therapy Dose Delivery Influences on Drug Therapy

Artificial Organs - Tập 27 Số 9 - Trang 808-814 - 2003
Bruce A. Mueller1,2, Deborah A. Pasko1,2, Kevin M. Sowinski1,2
1*Clinical Sciences Department, College of Pharmacy, University of Michigan, Ann Arbor, MI
2†School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, IN, U.S.A.

Tóm tắt

Abstract: Higher doses of renal replacement therapy have profound effects on pharmacotherapy, yet little research has been conducted in this area. High‐volume renal replacement therapies influence both the pharmacokinetic and the pharmacodynamic profiles of all drugs administered to these critically ill patients. Intermittent high‐dose “hybrid” hemodialysis therapies remove drugs to a much different degree than standard thrice‐weekly hemodialysis, yet pharmacokinetic studies have not been performed in patients receiving these therapies. High‐volume continuous renal replacement therapies offer dosing challenges not seen with standard low‐dose therapies. This article describes the pharmacokinetic and pharmacodynamic issues presented by high‐volume renal replacement therapies. Given the importance that pharmacotherapy has on optimal patient outcomes, a better understanding of the influence that high‐volume renal replacement therapy has on drugs is essential if these high volume therapies are to be used successfully in the intensive care unit.

Từ khóa


Tài liệu tham khảo

10.1002/j.1875-9114.1997.tb03707.x

10.1093/ndt/12.12.2647

Gilbert DN, 1999, The Sanford Guide to Antimicrobial Therapy

Aronoff GR, 1999, Drug Prescribing in Renal Failure, Dosing Guidelines for Adults

10.1053/ajkd.1998.v31.pm9631848

10.1007/s00134-002-1261-2

10.1007/s001340100963

10.1046/j.1523-1755.2002.00613.x

10.1097/00003246-200210000-00005

10.1016/S0140-6736(00)02430-2

10.1097/01.CCM.0000054866.45509.D0

10.1097/01.CCM.0000045182.90302.B3

10.1097/01.CCM.0000045183.74244.14

10.1016/S0272-6386(12)80811-0

10.1128/AAC.25.1.128

10.2165/00003088-199324050-00002

10.1007/BF01700172

10.1016/S0272-6386(99)70076-4

10.1128/AAC.44.6.1639-1644.2000

Kroh UF., 1995, Drug administration in critically ill patients with acute renal failure., New Horiz, 3, 748

10.1128/AAC.39.3.650

10.1053/ajkd.2000.8973

10.1086/516284

10.1300/J100v04n04_01

10.1002/j.1875-9114.1995.tb04335.x

10.1007/s001340051018

10.1128/AAC.37.5.1073

10.1128/AAC.42.3.521

10.1097/00024382-199602000-00011

10.1159/000063325

10.1046/j.1523-1755.63.s84.40.x

Hermsen ED, 2002, Enhanced clearance of fluconazole during sustained low‐efficiency dialysis., Blood Purif, 20, 315

Tegeder I, 1997, Pharmacokinetics of imipenem‐cilastatin in critically ill patients undergoing continuous venovenous hemofiltration., Antimicrobial Agents Chemother, 41, 2640, 10.1128/AAC.41.12.2640

10.1016/S0009-9236(99)70121-9

10.1007/s001340100857

10.1007/s002280000216

10.3109/08860229209047669

10.1046/j.1523-1755.56.s.72.2.x

Keller E., 1996, Pharmacokinetics during continuous renal replacement therapy., Int J Artif Organs, 19, 113, 10.1177/039139889601900212

10.1016/S0272-6386(12)81089-4

10.1038/clpt.1991.208

Thông tin
Thông tin xuất bản

Artificial Organs

Tập 27 Số 9

808-814

Thông tin tác giả